Dihydroetorphine

Structural formula
General
Surname	Dihydroetorphine
other names	(5 R , 6 R , 7 R , 9 R , 13 S , 14 R ) -7 - [( R ) -2-hydroxypentan-2-yl] -6-methoxy-17-methyl-4,5-epoxy- 6,14-ethanomorphinan-3-ol
Molecular formula	C 25 H 35 NO 4
External identifiers / databases
EC number	688-180-2
ECHA InfoCard	100.214.784
PubChem	107765
ChemSpider	96924
DrugBank	DB01450
Wikidata	Q1225158
Drug information
Drug class	analgesic
Mechanism of action	Opioid
properties
Molar mass	413.55 g · mol -1
safety instructions
H and P phrases	H: 300-330-361
	P: ?
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Dihydroetorphin is a medicinal substance with a strong analgesic effect ( analgesic ). In the experiment on the rat , the 11000-fold effect of morphine was found. Dihydroetorphin is only used in human medicine for the treatment of severe pain in China , where it was launched in 1992 . Since the active substance at peroral administration a very high first pass effect subject and thereby a very low bioavailability has, it is considered Sublingual tablet (dosage forms from 20 to 180 ug ) and as transdermal applied patch. In China, the active ingredient is also successfully used to replace opiate-dependent patients, for which sublingual application is preferred (comparable to buprenorphine substitution in the western world). Dihydroetorphine is subject to narcotics regulations. It is not marketable in Germany ( Annex I of the Narcotics Act ).

The active ingredient is by hydrogenation of etorphine prepared.

Individual evidence

↑ Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A label of [No public or meaningful name is available] in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on January 16, 2020, is derived from a self-classification by the distributor .
↑ ^a ^b Eberhard Schröder, Clemens Rufer, Ralph Schmiechen: Arzneimittelchemie I , Georg Thieme Verlag 1976, ISBN 3-13-520601-7 .
↑ Martin TJ, Hairston CT, Lutz PO, et al .: Anti-allodynic actions of intravenous opioids in the nerve injured rat: Potential utility of heroin and dihydroetorphine against neuropathic pain. European Journal of Pharmacology 1998; 357 (1): 25-32, PMID 9788770
↑ WHO Expert Committee on Drug Dependence: 31st Report. WHO Technical Report Series 887 (PDF; 1.4 MB), (1999).

[1] Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A label of [No public or meaningful name is available] in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on January 16, 2020, is derived from a self-classification by the distributor .

[SRS-2] Eberhard Schröder, Clemens Rufer, Ralph Schmiechen: Arzneimittelchemie I , Georg Thieme Verlag 1976, ISBN 3-13-520601-7 .

[3] Martin TJ, Hairston CT, Lutz PO, et al .: Anti-allodynic actions of intravenous opioids in the nerve injured rat: Potential utility of heroin and dihydroetorphine against neuropathic pain. European Journal of Pharmacology 1998; 357 (1): 25-32, PMID 9788770

[4] WHO Expert Committee on Drug Dependence: 31st Report. WHO Technical Report Series 887 (PDF; 1.4 MB), (1999).